Form 4: Denali Therapeutics Director Jay T. Flatley Receives Significant Equity Grant

Denali Therapeutics Inc. Director Jay T. Flatley was granted 6,037 Restricted Stock Units and 18,111 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Denali Therapeutics Inc. Director Jay T. Flatley reported the acquisition of 6,037 shares of common stock in the form of Restricted Stock Units (RSUs) on June 3, 2025, with a transaction price of $0.
• Each RSU represents a contingent right to receive one share of common stock, with 100% vesting upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Mr. Flatley also acquired 18,111 stock options (right to buy) on June 3, 2025, with an exercise price of $13.93 per share and an expiration date of June 3, 2035.
• Similar to the RSUs, 100% of the shares subject to the option shall vest upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Following these transactions, Mr. Flatley directly beneficially owns 16,220 shares of common stock (including the 6,037 unvested RSUs) and 18,111 derivative securities (stock options).
• Additionally, 336,313 shares of common stock are indirectly beneficially owned through The Flatley Family Trust, for which Mr. Flatley serves as a trustee.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is generally viewed positively as it aligns the director's interests with shareholders. It does not contain any negative or unexpected information.

Positives

• The grant of Restricted Stock Units and stock options to Director Jay T. Flatley aligns his financial interests directly with the long-term performance and shareholder value creation of Denali Therapeutics Inc.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned and structured equity compensation arrangement.

Future Outlook

The granted Restricted Stock Units and stock options are subject to a vesting schedule, which will occur upon the earlier of the one-year anniversary of the grant date (June 3, 2026) or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. The stock options have an expiration date of June 3, 2035.

Industry Context

Equity compensation, including Restricted Stock Units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel, including directors, by aligning their long-term interests with company performance and shareholder returns.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options for director compensation is a common and widely accepted practice across various industries, including biotechnology, as it ties executive and director incentives to the company's stock performance.
• The vesting schedule, typically over one year or tied to the next annual meeting, is also a standard approach for such grants, ensuring continued engagement and alignment.

Related Party Transactions

• Jay T. Flatley indirectly beneficially owns 336,313 shares of common stock through The Flatley Family Trust, for which he serves as a trustee. This indicates an existing related party relationship regarding share ownership.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Management/Employees: This transaction is part of the company's compensation structure, which can serve as a model for incentivizing other key personnel.

Next Steps

• Vesting of the 6,037 Restricted Stock Units upon the earlier of June 3, 2026, or the day preceding the Issuer's next annual meeting of stockholders.
• Vesting of the 18,111 stock options upon the earlier of June 3, 2026, or the day preceding the Issuer's next annual meeting of stockholders.
• Potential exercise of the stock options by June 3, 2035.

Key Dates

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, Rule 10b5-1